American Association for Cancer Research
19406207capr110532t-sup-f2_830k.pdf (830.57 kB)

Supplementary Figure 2 from The CDK4/6 Inhibitor PD0332991 Reverses Epithelial Dysplasia Associated with Abnormal Activation of the Cyclin-CDK-Rb Pathway

Download (830.57 kB)
journal contribution
posted on 2023-04-03, 19:29 authored by M. Carla Cabrera, Edgar S. Díaz-Cruz, Bhaskar V.S. Kallakury, Michael J. Pishvaian, Clinton J. Grubbs, Donald D. Muccio, Priscilla A. Furth

PDF file - 830K, TAg was effectively downregulated by doxycycline in submandibular salivary tissue of mice treated with pharmacological agents UAB30, rosiglitazone (ROSI) or PD0332991



Loss of normal growth control is a hallmark of cancer progression. Therefore, understanding the early mechanisms of normal growth regulation and the changes that occur during preneoplasia may provide insights of both diagnostic and therapeutic importance. Models of dysplasia that help elucidate the mechanisms responsible for disease progression are useful in highlighting potential targets for prevention. An important strategy in cancer prevention treatment programs is to reduce hyperplasia and dysplasia. This study identified abnormal upregulation of cell cycle–related proteins cyclin D1, cyclin-dependent kinase (CDK)4, CDK6, and phosphorylated retinoblastoma protein (pRb) as mechanisms responsible for maintenance of hyperplasia and dysplasia following downregulation of the initiating viral oncoprotein Simian virus 40 (SV40) T antigen. Significantly, p53 was not required for successful reversal of hyperplasia and dysplasia. Ligand-induced activation of retinoid X receptor and PPARγ agonists attenuated cyclin D1 and CDK6 but not CDK4 or phosphorylated pRb upregulation with limited reversal of hyperplasia and dysplasia. PD0332991, an orally available CDK4/6 inhibitor, was able to prevent upregulation of cyclin D1 and CDK6 as well as CDK4 and phosphorylated pRb and this correlated with a more profound reversal of hyperplasia and dysplasia. In summary, the study distinguished CDK4 and phosphorylated pRb as targets for chemoprevention regimens targeting reversal of hyperplasia and dysplasia. Cancer Prev Res; 5(6); 810–21. ©2012 AACR.